ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,930.57
0.82%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) News

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:OKYO
DateTimeSourceHeadlineSymbolCompany
09/04/202409:00UK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
02/04/202422:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
22/03/202422:00UK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
21/03/202422:00UK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
20/03/202422:00UK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
09/02/202423:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
09/02/202423:00UK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
31/01/202423:00UK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
22/05/202317:15UK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
22/05/202317:00UK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
19/05/202320:22Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
19/05/202317:00RNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
15/05/202316:00UK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
11/05/202323:27Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
11/05/202321:00RNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
11/05/202316:00UK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
03/05/202322:00UK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
03/05/202316:00RNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
03/05/202305:16Alliance NewsAlliance NewsTRADING UPDATES: Knights Group buys St James Law and Baines WilsonLSE:OKYOOkyo Pharma Limited
02/05/202316:00UK RegulatoryOKYO Pharma Limited First-Patient First-Visit for Phase 2 TrialLSE:OKYOOkyo Pharma Limited
26/04/202301:19Alliance NewsAlliance NewsTRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facilityLSE:OKYOOkyo Pharma Limited
25/04/202316:00UK RegulatoryOKYO Pharma Limited Activation of First Clinical Trial Site in the U.SLSE:OKYOOkyo Pharma Limited
05/04/202316:00UK RegulatoryOKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATIONLSE:OKYOOkyo Pharma Limited
04/04/202318:08Alliance NewsAlliance NewsOkyo Pharma applies to delist from London Stock Exchange due to costsLSE:OKYOOkyo Pharma Limited
04/04/202316:00UK RegulatoryOKYO Pharma Limited Notice Of Intention To Delist From The LSELSE:OKYOOkyo Pharma Limited
30/03/202317:00UK RegulatoryOKYO Pharma Limited Director Acquires SharesLSE:OKYOOkyo Pharma Limited
29/03/202317:00UK RegulatoryOKYO Pharma Limited Director acquires sharesLSE:OKYOOkyo Pharma Limited
24/03/202318:00UK RegulatoryOKYO Pharma Limited Director/PDMR ShareholdingLSE:OKYOOkyo Pharma Limited
16/03/202318:01RNS Non-RegulatoryOKYO Pharma Limited Listing of Trial on the ClinicalTrials.gov WebsiteLSE:OKYOOkyo Pharma Limited
16/03/202318:00UK RegulatoryOKYO Pharma Limited Closing of Global Private PlacementLSE:OKYOOkyo Pharma Limited
 Showing the most relevant articles for your search:LSE:OKYO

Your Recent History

NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
ASX
BHP
BHP
NYSE
DIS
Walt Disney
ASX
XFL
S&P ASX 50
ASX
NCM
Newcrest Mining
NASDAQ
NVDA
NVIDIA
ASX
TLS
Telstra
FX
EURAUD
Euro vs AUD
NYSE
NKE
Nike
ASX
ANZ
Australia And New Zealan...
ASX
XAO
Australian SE All Ordina...
ASX
ORG
Origin Energy
ASX
MQG
Macquarie
NASDAQ
MSFT
Microsoft
ASX
NAB
National Australia Bank
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved